SI1633748T1 - Kinolinski derivati kot inhibitorji fosfodiesteraze - Google Patents

Kinolinski derivati kot inhibitorji fosfodiesteraze

Info

Publication number
SI1633748T1
SI1633748T1 SI200430691T SI200430691T SI1633748T1 SI 1633748 T1 SI1633748 T1 SI 1633748T1 SI 200430691 T SI200430691 T SI 200430691T SI 200430691 T SI200430691 T SI 200430691T SI 1633748 T1 SI1633748 T1 SI 1633748T1
Authority
SI
Slovenia
Prior art keywords
phosphodiesterase inhibitors
quinoline derivatives
quinoline
derivatives
phosphodiesterase
Prior art date
Application number
SI200430691T
Other languages
English (en)
Slovenian (sl)
Inventor
Ian Robert Baldwin
Michael David Barker
Anthony William Dean
Colin David Eldred
Brian Evans
Sharon Lisa Gough
Stephen Barry Guntrip
Julie Nicole Hamblin
Stuart Holman
Paul Jones
Mika Kristian Lindvall
Christopher James Lunniss
Tracy Jane Redfern
Alison Judith Redgrave
John Edward Robinson
Michael Woodrow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0311688A external-priority patent/GB0311688D0/en
Priority claimed from GB0326187A external-priority patent/GB0326187D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SI1633748T1 publication Critical patent/SI1633748T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200430691T 2003-05-21 2004-05-19 Kinolinski derivati kot inhibitorji fosfodiesteraze SI1633748T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0311688A GB0311688D0 (en) 2003-05-21 2003-05-21 Compounds
GB0326187A GB0326187D0 (en) 2003-11-10 2003-11-10 Compounds
EP04733799A EP1633748B1 (en) 2003-05-21 2004-05-19 Quinoline derivatives as phosphodiesterase inhibitors
PCT/EP2004/005494 WO2004103998A1 (en) 2003-05-21 2004-05-19 Quinoline derivatives as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
SI1633748T1 true SI1633748T1 (sl) 2008-08-31

Family

ID=33477765

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200430691T SI1633748T1 (sl) 2003-05-21 2004-05-19 Kinolinski derivati kot inhibitorji fosfodiesteraze
SI200431802T SI1944305T1 (sl) 2003-05-21 2004-05-19 Kinolinski derivati kot fosfodiesterazni inhibitorji

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200431802T SI1944305T1 (sl) 2003-05-21 2004-05-19 Kinolinski derivati kot fosfodiesterazni inhibitorji

Country Status (30)

Country Link
US (4) US7566786B2 (enExample)
EP (2) EP1944305B1 (enExample)
JP (1) JP4625460B2 (enExample)
KR (1) KR101144548B1 (enExample)
CN (1) CN1823063B (enExample)
AR (1) AR044401A1 (enExample)
AT (2) ATE388148T1 (enExample)
AU (1) AU2004240759B2 (enExample)
BR (1) BRPI0410477A (enExample)
CA (1) CA2526228C (enExample)
CO (1) CO5700780A2 (enExample)
CY (2) CY1108094T1 (enExample)
DE (1) DE602004012260T2 (enExample)
DK (2) DK1633748T3 (enExample)
EG (1) EG24774A (enExample)
ES (2) ES2301993T3 (enExample)
HR (2) HRP20080236T3 (enExample)
IL (1) IL171726A (enExample)
IS (1) IS2581B (enExample)
MA (1) MA27808A1 (enExample)
MX (1) MXPA05012466A (enExample)
NO (1) NO330754B1 (enExample)
NZ (1) NZ543554A (enExample)
PL (2) PL1633748T3 (enExample)
PT (2) PT1944305E (enExample)
RU (1) RU2335493C2 (enExample)
SI (2) SI1633748T1 (enExample)
TW (1) TWI328009B (enExample)
WO (1) WO2004103998A1 (enExample)
ZA (1) ZA200509319B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0425572D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd 1,7-Naphthyridines
JP5281291B2 (ja) 2005-01-10 2013-09-04 グラクソ グループ リミテッド 新規化合物
GB0503955D0 (en) * 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
GB0505621D0 (en) * 2005-03-18 2005-04-27 Glaxo Group Ltd Novel compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2621406A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US7829713B2 (en) * 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
CA2644850A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
GB0605462D0 (en) * 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
WO2007125952A1 (ja) * 2006-04-28 2007-11-08 Shionogi & Co., Ltd. Ｎｐｙ ｙ５受容体拮抗作用を有するアミン誘導体
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
CN102239149B (zh) 2008-10-06 2015-05-13 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
JP2012513464A (ja) * 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
CA2749403A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411517A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US8394829B2 (en) * 2010-05-10 2013-03-12 Gilead Sciences, Inc. Bi-functional quinoline analogs
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20130225524A1 (en) * 2010-11-05 2013-08-29 Deping Chai Chemical Compounds
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
JP6026441B2 (ja) * 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
US9278960B2 (en) * 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
BR122021012629B1 (pt) 2013-02-01 2022-06-07 Wellstat Therapeutics Corporation Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
CN108299425B (zh) * 2015-03-24 2020-09-18 上海璎黎药业有限公司 稠环衍生物、其制备方法、中间体、药物组合物及应用
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
CA3047579A1 (en) * 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
BR112023011284A2 (pt) 2020-12-09 2024-02-06 Wellstat Therapeutics Corp Composto de imidazoquinolina com atividade anti-inflamatória, antifúngica, antiparasítica e antineoplásica
TW202430172A (zh) * 2023-01-17 2024-08-01 大陸商瑞石生物醫藥有限公司 Ｐｄｅ４抑制劑、其製備方法及其在醫藥上的應用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE46886B1 (en) 1977-05-17 1983-10-19 Allen & Hanburys Ltd Aminoalkyl-benzene derivatives
EP0048005A3 (de) * 1980-09-17 1983-01-19 ALFA-Institut für hauswirtschaftliche Produkt- und Verfahrens-Entwicklung GmbH Vorrichtung zum Stapeln von Geschirr
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE69128682T2 (de) 1990-03-28 1998-06-04 Otsuka Pharma Co Ltd Chinolinderivat, antiulcus-mittel das dieses derivat enthält und darstellung dieses derivates
US5214191A (en) 1990-05-22 1993-05-25 Cortech, Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
EP1281770B1 (en) 1993-03-10 2010-03-03 GlaxoSmithKline LLC Human brain phosphodiesterase and screening method
FR2705346B1 (fr) 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
EP0957087B1 (en) 1994-06-15 2002-12-04 The Wellcome Foundation Limited Intermediates useful in the preparation of enzyme inhibitors
JP2000510866A (ja) * 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
CN1252054C (zh) 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
GB9712761D0 (en) * 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
EP1042295B1 (en) 1997-12-22 2005-09-07 Pharmacia & Upjohn Company LLC 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
HU230728B1 (hu) 1998-09-29 2017-12-28 Wyeth Holdings Llc Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
CZ303899B6 (cs) 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
MY121142A (en) 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
DK1161438T3 (da) 1999-03-15 2004-08-30 Abbott Lab 6-O-substituerede makrolider, som har antibakteriel aktivitet
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
CN1452619A (zh) 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
AR035205A1 (es) 2000-09-29 2004-05-05 Glaxo Group Ltd Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
WO2002036570A1 (en) 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
JP4623962B2 (ja) 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
CN1662521A (zh) 2002-06-20 2005-08-31 比奥维特罗姆股份公司 可用于治疗肥胖、ii型糖尿病和cns障碍的新化合物
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322722D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
ES2301993T3 (es) 2008-07-01
RU2335493C2 (ru) 2008-10-10
EP1944305A1 (en) 2008-07-16
NO20055421L (no) 2005-12-20
HRP20110957T1 (hr) 2012-01-31
EP1633748B1 (en) 2008-03-05
AU2004240759B2 (en) 2010-03-04
NO20055421D0 (no) 2005-11-16
EP1944305B1 (en) 2011-10-19
KR20060015278A (ko) 2006-02-16
MA27808A1 (fr) 2006-03-01
JP2007501264A (ja) 2007-01-25
CA2526228A1 (en) 2004-12-02
HK1092458A1 (en) 2007-02-09
HK1118274A1 (en) 2009-02-06
DE602004012260T2 (de) 2009-03-12
ZA200509319B (en) 2007-02-28
ES2374850T3 (es) 2012-02-22
BRPI0410477A (pt) 2006-05-30
CY1112232T1 (el) 2015-12-09
US7566786B2 (en) 2009-07-28
US20070049570A1 (en) 2007-03-01
IS2581B (is) 2010-02-15
DK1633748T3 (da) 2008-06-30
PL1633748T3 (pl) 2008-07-31
JP4625460B2 (ja) 2011-02-02
NZ543554A (en) 2008-09-26
AU2004240759A1 (en) 2004-12-02
DE602004012260D1 (enExample) 2008-04-17
CO5700780A2 (es) 2006-11-30
NO330754B1 (no) 2011-07-04
PL1944305T3 (pl) 2012-03-30
US20090312325A1 (en) 2009-12-17
MXPA05012466A (es) 2006-01-30
ATE388148T1 (de) 2008-03-15
DK1944305T3 (da) 2012-01-30
PT1944305E (pt) 2012-01-11
IL171726A (en) 2013-07-31
WO2004103998A1 (en) 2004-12-02
ATE529421T1 (de) 2011-11-15
KR101144548B1 (ko) 2012-05-11
TW200500358A (en) 2005-01-01
US20070142373A1 (en) 2007-06-21
PT1633748E (pt) 2008-05-20
HRP20080236T3 (en) 2008-06-30
CY1108094T1 (el) 2014-02-12
EP1633748A1 (en) 2006-03-15
US20060178416A1 (en) 2006-08-10
EG24774A (en) 2010-08-19
IS8110A (is) 2005-10-31
CA2526228C (en) 2010-08-03
AR044401A1 (es) 2005-09-14
SI1944305T1 (sl) 2012-02-29
TWI328009B (en) 2010-08-01
CN1823063A (zh) 2006-08-23
US7572915B2 (en) 2009-08-11
RU2005135016A (ru) 2006-06-27
CN1823063B (zh) 2010-07-14

Similar Documents

Publication Publication Date Title
ZA200509319B (en) Quinoline derivatives as phosphodiesterase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL175947A0 (en) Novel quinoline derivatives
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
EP1848430A4 (en) NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS
PL1789041T3 (pl) Pochodne arylopirydyny jako inhibitory 11-beta-HSD1
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
SG131944A1 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
IL183851A0 (en) Heteroaromatic quinoline compounds and their use as pde10 inhibitors
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
IL172793A0 (en) Nicotinamide derivatives useful as pde4 inhibitors
GB0317484D0 (en) Nicotinamide derivatives useful as pde4 inhibitors
GB0317516D0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
GB0317482D0 (en) Nicotinamide derivatives useful as pde4 inhibitors
EG24415A (en) Quinoline derivatives
GB0317509D0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
GB0317472D0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB0205936D0 (en) Methylxanthine derivatives as Pl-3kinases inhibitors
HK1086560A (en) Thienopyridone derivatives as kinase inhibitors